This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
The public conference will be held on March 15, 2017, from 8:30 a.m. to 5 p.m.; March 16, 2017, from 8:30 a.m. to 5 p.m.; and March 17, 2017, from 8:30 a.m. to 12:20 p.m. The conference is preceded by a Welcome Reception on March 14, 2017, from 5 p.m. to 7 p.m. See the SUPPLEMENTARY INFORMATION section for registration date and information.
Table of Contents
Enhanced Content - Table of Contents
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
191
as of
08/11/2026 at 6:15 am EDT
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2017-03176 as it appeared on Public Inspection on
02/16/2017 at 8:45 am.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2017-03176 (82 FR 11043)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice of public conference.
SUMMARY:
The Food and Drug Administration (FDA) Cincinnati District, in co-sponsorship with Xavier University, is announcing a public conference entitled “FDA/Xavier University PharmaLink Conference: Leadership in a Global Supply Chain.” The PharmaLink conference seeks solutions to important and complicated issues by aligning with the strategic priorities of FDA, and includes presentations from key FDA officials and industry experts.
DATES:
The public conference will be held on March 15, 2017, from 8:30 a.m. to 5 p.m.; March 16, 2017, from 8:30 a.m. to 5 p.m.; and March 17, 2017, from 8:30 a.m. to 12:20 p.m. The conference is preceded by a Welcome Reception on March 14, 2017, from 5 p.m. to 7 p.m. See the
SUPPLEMENTARY INFORMATION
section for registration date and information.
ADDRESSES:
The public conference will be held on the campus of Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207, 513-745-3073 or 513-745-3483.
FOR FURTHER INFORMATION CONTACT:
For information regarding this notice:
Nicholas Paulin, Food and Drug Administration, Cincinnati South Office, 36 East 7th St., Cincinnati, OH 45202, 513-246-4134, email:
nicholas.paulin@fda.hhs.gov.
For information regarding the conference and registration:
Marla Phillips, Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207-5471, 513-745-3073, email:
phillipsm4@xavier.edu.
SUPPLEMENTARY INFORMATION:
I. Background
The public conference helps fulfill the Department of Health and Human Services' and FDA's important mission to protect the public health. The most pressing challenges of the global pharmaceutical industry require solutions which are inspired by collaboration to ensure the on-going health and safety of patients. These challenges include designing products with the patient in mind, building quality into the product from the starting point, selecting the right suppliers, and considering total product lifecycle systems. Meeting these challenges requires vigilance, innovation, supply chain strategy, relationship management, proactive change management, and a commitment to doing the job right the first time. FDA has made education of the drug and device manufacturing community a high priority to help ensure the quality of FDA-regulated drugs and devices.
The conference helps to achieve objectives set forth in section 406 of the Food and Drug Administration Modernization Act of 1997 (21 U.S.C. 393), which includes working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public. The conference also is consistent with the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121) by providing outreach activities by Government Agencies to small businesses.
The conference includes the following:
Welcome Reception at the Hilton Netherland Plaza.
Lunch Networking by Topic.
The Solution “Xchange”.
Case Studies and Small Group Discussions.
Action Plans.
II. Topics for Discussion at the Public Conference
The public conference will engage those involved in FDA-regulated global supply chain quality and management through the following topics:
FDA Metrics Program—Path Forward to Reduce Risks Within FDA and Across Industry.
Predictive Capabilities Through a Living Metrics Model.
How Big Data and Artificial Intelligence Can Enhance Your Proactive Risk Monitoring Programs.
Connecting Culture to Performance.
Data Integrity—Detection and Successful Practices.
Building a Bridge Across Generations.
Good Supply Practices (GSPs)—Paradigm Shifting Solutions.
How to Develop and Execute a Robust Risk-Based Due Diligence Plan.
Maximizing Post-Merger Success.
Your Company Bought a New Business—Now What?
Supply Chains in China—Strategies for Regulatory Success.
Top 3 Challenges for Successful Serialization Implementation Across Your Supply Chain.
Strategic Direction of the Food & Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Manufacturing Quality.
Office of Regulatory Affairs Key Initiatives.
FDA Investigator Case Study Insights.
III. Registration for the Public Conference
Registration:
To register online for the public conference, please visit the “Registration” link on the conference Web site at
http://www.XavierPharmaLink.com.
Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone. FDA has verified the Web site address in this document, as of the date this document publishes in the
Federal Register
, but Web sites are subject to change over time.
To register by mail, please send your name, title, firm name, address, telephone and fax numbers, email, and payment information for the fee to Xavier University, Attention: Marla Phillips, 3800 Victory Pkwy., Cincinnati, OH 45207-5471. An email will be sent confirming your registration.
If you need special accommodations due to a disability, please contact Marla Phillips (see
FOR FURTHER INFORMATION CONTACT
) at least 7 days in advance of the conference.
There is a registration fee. The conference registration fees cover the cost of the presentations, training materials, receptions, breakfasts, lunches, and dinners for the 2.5 days of the conference, including the Welcome Reception that precedes the conference. There will be onsite registration if space is available. The cost of registration is as follows:
Table 1—Registration Fees 1
Attendee type
Standard rate
Industry
$1,895
Small Business (<100 employees)
1,295
Start-up Manufacturer
300
Academic
300
Media
Free
( printed page 11044)
Government
Free
1
The fourth registration from the same company is free. Payment for the three paying registrants must be made prior to registering the fourth person free.
The following forms of payment will be accepted: American Express, Visa, Mastercard, and company checks.
Attendees are responsible for their own accommodations. The conference headquarter hotel is the Downtown Cincinnati Hilton Netherlands Plaza, 35 West 5th St., Cincinnati, OH 45202, 513-421-9100. To make reservations online, please visit the “Venue & Logistics” link at
http://www.XavierPharmaLink.com.
The hotel is expected to sell out during this timeframe, so early reservation in the conference room-block is encouraged.